Miromatrix to Report Fourth Quarter and Full Year 2022 Financial Results
Miromatrix Medical Inc. (NASDAQ: MIRO), a leader in bioengineering fully transplantable organs, will announce its fourth quarter and full year 2022 financial results on March 31, 2023, after market close.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Miromatrix Medical Inc. (NASDAQ: MIRO), a leader in bioengineering fully transplantable organs, will announce its fourth quarter and full year 2022 financial results on March 31, 2023, after market close. Management will conduct a conference call at 3:30 PM CT to discuss these results. Interested parties can join the call via domestic and international numbers or through a live webcast on the company's investor relations webpage. Miromatrix focuses on utilizing its proprietary perfusion technology to address the shortage of human organs, specifically developing applications for human livers and kidneys.
Details
News Market Reaction – MIRO
The recorded move for MIRO in the trading session of this news was +3.45%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
EDEN PRAIRIE, Minn., March 15, 2023 (GLOBE NEWSWIRE) -- Miromatrix Medical Inc. (NASDAQ: MIRO), a life sciences company pioneering a novel technology for bioengineering fully transplantable organs to help save and improve patients’ lives, today announced that the Company will report financial results for the fourth quarter and full year 2022 after market close on Friday, March 31, 2023. Company management will host a corresponding conference call beginning at 3:30 pm Central Time / 4:30 pm Eastern Time.
Individuals interested in listening to the conference call may do so by dialing 877-407-3982 for domestic callers or 201-493-6780 for international callers. Please reference Conference ID: 13736060. To listen to a live webcast, please visit the investor relations section of Miromatrix's website at: https://miromatrix.gcs-web.com/
About Miromatrix
Miromatrix is a life sciences company pioneering a novel technology for bioengineering fully transplantable human organs to help save and improve patients’ lives. Miromatrix has developed a proprietary perfusion technology platform for bioengineering organs that it believes will efficiently scale to address the shortage of available human organs. Miromatrix’s initial development focus is on human livers and kidneys. For more information, visit miromatrix.com.
Investor Contact
Greg Chodaczek
347-620-7010
ir@miromatrix.com
Media Contact:
press@miromatrix.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.